One of the new projects brings together Data-Driven Life Science (DDLS) fellow Muhammad Arif from the University of Gothenburg and Associate Principal Scientist Claudia Correia, PhD, from BioPharmaceuticals R&D at AstraZeneca— to explore and showcase the power of integrating clinical, molecular, and data-driven research.
Aiming for novel therapeutic targets
The project focuses on progressive Peripheral Artery Disease (PAD), a common but often underdiagnosed and undertreated cardiovascular condition.
The aim of this research project is to uncover key disease drivers and identify potential biomarkers as well as novel therapeutic targets. We are excited to get started, and expect a lot of valuable outcomes from this collaboration,
Claudia Correia said during the introductory seminar.
PAD is caused by atherosclerotic narrowing of peripheral arteries, primarily affecting the lower limbs, resulting in reduced blood flow in the muscles. This can lead to muscle damage, pain, limited mobility, and, in severe cases, amputation. Despite its prevalence and impact, the underlying mechanisms of muscle tissue injury remain poorly understood.
To address this, the team will use a unique set of clinical samples to conduct multi-omics analyses—including metabolomics, proteomics, and RNA sequencing.
A boost for careers and research
The ongoing partnership with AstraZeneca, which has been ongoing since the start of WCMTM 2015, plays a key role in strengthening and accelerating life science research in the Gothenburg area.
“We are also glad to see valuable outcomes such as joint publications, and to support development for postdocs, as moving between academia and industry is a natural and important career path,” said Johan Zelano, Director of WCMTM.
